【一品红：AR882全球III期临床进展顺利，有望抢占痛风治疗市场】金十数据4月23日讯，一品红宣布其在研全球1类创新药AR882全球III期临床快速进展，目前全球已入组上千人。AR882是去年美国食品药品监督管理局授予给中国企业快速通道资格中唯一非肿瘤类药物，用于痛风石研究，有望填补痛风石治疗领域口服药物的全球空白。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.